Literature DB >> 15942547

Medications as adjunct therapy for weight loss: approved and off-label agents in use.

Susan B Moyers1.   

Abstract

Although a nutritionally balanced, energy-controlled diet and regular exercise form the cornerstone of weight management, supporting therapies may include antiobesity medications when a clinician determines that pharmacologic assistance could contribute to treatment success. The US Food and Drug Administration has approved certain medications for helping achieve weight loss in patients with obesity or overweight who have comorbidities. However, some clinicians prescribe medications not approved for weight loss for this purpose. Evidence from clinical trials indicates that weight loss resulting from the use of many of these off-label pharmaceutical agents is modest, but in a range that correlates with favorable modification of cardiovascular risk factors, and significant when compared with placebo plus diet and lifestyle modification. Clinical trials also demonstrate a slight but significant effect in the weight-maintenance phases following weight loss. Pharmacotherapy alone, without behavior modification, is not effective; patients who respond to medication typically regain weight when the drug is discontinued. The fact that many weight-loss medications are sold over the Internet without a prescription suggests that they are being used without medical supervision. The purpose of this review is to present evidence for and against the obesity medications currently used in clinical practice, and the possible role for these agents in a person's overall weight loss plan.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15942547     DOI: 10.1016/j.jada.2005.03.010

Source DB:  PubMed          Journal:  J Am Diet Assoc        ISSN: 0002-8223


  10 in total

Review 1.  Orlistat: Current issues for patients with type 2 diabetes.

Authors:  Juliet M Mancino
Journal:  Curr Diab Rep       Date:  2006-11       Impact factor: 4.810

Review 2.  Appetite suppressants, cardiac valve disease and combination pharmacotherapy.

Authors:  Richard B Rothman; Michael H Baumann
Journal:  Am J Ther       Date:  2009 Jul-Aug       Impact factor: 2.688

3.  Comparison of orlistat and sibutramine in an obesity management program: efficacy, compliance, and weight regain after noncompliance.

Authors:  A Gursoy; M F Erdogan; M O Cin; M Cesur; N Baskal
Journal:  Eat Weight Disord       Date:  2006-12       Impact factor: 4.652

4.  D1 and D2 antagonists reverse the effects of appetite suppressants on weight loss, food intake, locomotion, and rebalance spiking inhibition in the rat NAc shell.

Authors:  B Kalyanasundar; Claudia I Perez; Alvaro Luna; Jessica Solorio; Mario G Moreno; David Elias; Sidney A Simon; Ranier Gutierrez
Journal:  J Neurophysiol       Date:  2015-05-13       Impact factor: 2.714

5.  The use of TeleMedicine in the treatment of paediatric obesity: feasibility and acceptability.

Authors:  Ann McGrath Davis; Rochelle L James; Richard E Boles; Jeannine R Goetz; John Belmont; Brett Malone
Journal:  Matern Child Nutr       Date:  2011-01       Impact factor: 3.092

6.  Posttraumatic stress disorder in male military veterans with comorbid overweight and obesity: psychotropic, antihypertensive, and metabolic medications.

Authors:  W Victor R Vieweg; Demetrios A Julius; Antony Fernandez; Daniel M Tassone; Shireesha N Narla; Anand K Pandurangi
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2006

7.  Inhibitory effect of a weight-loss Chinese herbal formula RCM-107 on pancreatic α-amylase activity: Enzymatic and in silico approaches.

Authors:  Shiqi Luo; George Binh Lenon; Harsharn Gill; Andrew Hung; Daniel A Dias; Mingdi Li; Linh Toan Nguyen
Journal:  PLoS One       Date:  2020-04-29       Impact factor: 3.240

8.  Obesity: prevalence, theories, medical consequences, management, and research directions.

Authors:  Colin Wilborn; Jacqueline Beckham; Bill Campbell; Travis Harvey; Melyn Galbreath; Paul La Bounty; Erika Nassar; Jennifer Wismann; Richard Kreider
Journal:  J Int Soc Sports Nutr       Date:  2005-12-09       Impact factor: 5.150

9.  Antidiabetic activity of the ethyl acetate fraction of Ficus lutea (Moraceae) leaf extract: comparison of an in vitro assay with an in vivo obese mouse model.

Authors:  Oyinlola O Olaokun; Lyndy J McGaw; Ilse Janse van Rensburg; Jacobus N Eloff; Vinny Naidoo
Journal:  BMC Complement Altern Med       Date:  2016-03-31       Impact factor: 3.659

10.  Topiramate-related adverse events: Pattern and signals in the Korea Adverse Event Reporting System, 2010-2017.

Authors:  Junyeong Choi; Dongwon Yoon; Minhee Park; Kyung-In Joung; Ju-Young Shin
Journal:  Medicine (Baltimore)       Date:  2020-10-16       Impact factor: 1.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.